This was confirmed in the randomized Phase III trials, DESTINY-Breast 02 and DESTINY-Breast 03, involving patients with inoperable or metastatic HER2-positive breast cancer who had previously received trastuzumab- and taxane-based therapies [6]. This evidence concerns the gene ERBB2 and breast cancer.